SubHero Banner

Opdivo® (nivolumab) – New indication

August 1, 2017 – Bristol-Myers Squibb announced the FDA approval of Opdivo (nivolumab) for the treatment of adult and pediatric (12 years and older) patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.

Download PDF